Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Johnson & Johnson Plans Move Into Vaccines With Bid For Remainder Of Crucell

This article was originally published in The Pink Sheet Daily

Executive Summary

Deal could position the pharma giant to eventually become a sixth major player in the worldwide vaccine space.
Advertisement

Related Content

Janssen R&D Unveils Three New Research Platforms
Merck Serono, J&J Step Up Investment For Local Chinese Market With Manufacturing Sites
Intercell's Pipeline Setbacks Force Strategic Rethink, Highlight Downside of Option-Based Deals
J&J's Magnificent Seven: Aging Blockbusters Carry Firm As New Launches Come Along
In Advance Of HSV-2 Vaccine Trials, Genocea Taps Investors For $35 Million
Flu Vaccines, Increased Focus On Preventive Medicine Pique J&J's Interest In Crucell
J&J Obtains Approval By Crucell's Boards For Proposed Purchase
J&J Buys $440 Mil. Stake In Crucell; Will Collaborate On Universal Flu Vaccine
J&J Buys $440 Mil. Stake In Crucell; Will Collaborate On Universal Flu Vaccine
Wyeth Calls Off Plan To Acquire Crucell

Topics

Advertisement
UsernamePublicRestriction

Register

PS071192

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel